Marker Therapeutics Initiated at Buy by Ladenburg Thalmann
Marker Therapeutics Initiated at Buy by Ladenburg Thalmann
Dow JonesApr 30 10:13 ET
Express News | Ladenburg Thalmann Initiates Coverage On Marker Therapeutics With Buy Rating, Announces Price Target of $11
BenzingaApr 30 10:03 ET
Marker Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/30/2024 174.31% Ladenburg Thalmann → $11 Initiates Coverage On → Buy 02/17/2022 -75.06% Roth Capital $3
BenzingaApr 30 10:01 ET
Marker Therapeutics' MT-601 Shows Promising Results
TipRanksApr 8 12:07 ET
Marker Therapeutics Advances in Immuno-Oncology
TipRanksMar 26 13:07 ET
Marker Therapeutics GAAP EPS of -$1.59, Revenue of $3.31M
Seeking AlphaMar 26 01:13 ET
Express News | Marker Therapeutics Reports 2023 Net Loss Of $(8.2)M Vs. Net Loss Of $(29.9)M Last Year
Moomoo 24/7Mar 25 17:56 ET
Press Release: Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response
Dow JonesMar 25 17:45 ET
Marker Therapeutics Ends Stock Sale Deal With LPC
TipRanksMar 1 08:12 ET
Express News | Marker Therapeutics Receives Approval From United States Adopted Name Council and International Nonproprietary Names Expert Committee for "Neldaleucel" as Nonproprietary Name for MT-601
Moomoo 24/7Jan 22 07:46 ET
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced a restructuring of its clinical programs and a strategic prioritization of its multi-tumor associated antigen (multiTAA)-specific T cell product pipeline. In addition, the Company reported a clinical update on the Phase 2 ARTEMIS study investigating MT-401, a multiTAA-specific T cell product, for the treatment of patients with acute myeloid leukemia (AML).
GlobeNewswireJan 8 08:24 ET
Express News | Marker Therapeutics Says 'MultiTAA-specific T Cell Therapies Demonstrate Clinical Safety and Positive Clinical Data Across Multiple Indications'
Moomoo 24/7Jan 8 07:30 ET
Express News | Marker Therapeutics Says 'Strategic Prioritization of Clinical Programs With Focus on MT-601 in Patients With Lymphoma'
Moomoo 24/7Jan 8 07:30 ET
Express News | Marker Therapeutics Announces Clinical Program Updates And Pipeline Prioritization
Moomoo 24/7Jan 8 07:29 ET
12 Health Care Stocks Moving In Friday's After-Market Session
GainersStrata Skin Sciences (NASDAQ:SSKN) shares moved upwards by 60.0% to $0.88 during Friday's after-market session. The company's market cap stands at $30.8 million. Cue Health (NASDAQ:HLTH) shares
BenzingaDec 29, 2023 16:31 ET
Palatin Technologies, Cellectis Among Healthcare Movers
Seeking AlphaDec 29, 2023 10:00 ET
PSTX, MRKR and GPRO Among Pre-market Losers
Seeking AlphaDec 12, 2023 08:39 ET
Top Midday Gainers
Marker Therapeutics (MRKR) said the "sustained complete response in our first patient treated with MT-601 over six months has been an encouraging and rewarding experience" in the phase 1 study. The "r
MT NewswiresDec 11, 2023 13:53 ET
GTHX, MRKR and CLIR Among Mid-day Movers
Seeking AlphaDec 11, 2023 12:51 ET
Express News | Marker Therapeutics Shares Are Trading Higher After the Company Reported a Clinical Update on the APOLLO Study
Moomoo 24/7Dec 11, 2023 12:25 ET
No Data
No Data